SLC22 GENE FAMILY
The SLC22 gene family encodes for more than 30 proteins, some of them acting as organic cation transporters (OCTs), organic cation and zwitterion transporters (OCTNs) and organic anion transporters (OATs). OCTs, OCTNs and organic anion transporters, show broad substrate selectivity, being able to transport multiple compounds different in size and structure.
HUMAN ORGANIC CATION TRANSPORTERS (HOCTS)
Organic cation transporters (OCT1-3), such as many transporters in the SLC22 family, have a predicted membrane topology of 12 α-helical transmembrane domains (TMDs), an intracellular N terminus, a large glycosylated extracellular loop between TMDs 1 and 2, a large intracellular loop with phosphorylation sites between TMDs 6 and 7 and an intracellular C terminus. OCTs are equilibrative transporters. Translocation of cations by these transporters is also electrogenic. Thus, the membrane potential might serve as a driving force in addition to the concentration gradient. They can translocate a broad variety of substrates with highly variable molecular structures, and similarly, they can also be inhibited by a large number of compounds, which are able to interact with the transporters without being translocated. OCTs are potentially bidirectional transporters able to interact with inhibitors with different affinities depending on the site of drugtransporter interaction. 1 OCT substrates include endogenous compounds, drugs, xenobiotics as well as a variety of model substrates, which are routinely used for OCT function assays. Most substrates and inhibitors of OCTs broadly overlap among the different members of the family. 2, 3 
HOCT1
The first organic cation transporter (rOCT) was cloned from rat kidney in 1994. 4 Some years later the mouse (mOCT1) 5 and rabbit orthologues (rbOCT1) 6 were isolated. hOCT1 was independently cloned by two groups. 7, 8 A difference between both human complementary DNA clones resulting in three amino-acid substitutions was observed being the human orthologue 78% identical to rOCT1. 9 hOCT1 is encoded by the SLC22A1 gene, which contains 11 exons and 10 introns localised on chromosome 6.q26-7. 10 Although OCT1 is highly conserved in mammals, only a few amino acids are also conserved in fish, Drosophila melanogaster or Caenorhabditis elegans (Figure 1 ). OCT1 protein is expressed mostly in epithelial cells. Regarding its tissue distribution, hOCT1 is mainly expressed in the liver, where it is located at the sinusoidal membrane of the hepatocytes. 11 OCT1 orthologues in rat, mouse and rabbit are also expressed strongly in kidney, although SLC22A1 messenger RNA abundance in human renal tissue appears to be low. 10, 12 Nevertheless, the OCT1 protein has been identified although differentially localized in rat (basolateral membrane of proximal tubules), 10 and human kidneys (localised at the apical and subapical domains of both proximal and distal tubules). 12 hOCT1 is also expressed in many other organs including small intestine, at the brush border membrane; lung, at the luminal membrane of bronchial epithelial cells; heart; skeletal muscle; brain, in endothelial cells of microvessels; placenta; mammary gland; adrenal gland; eye, in cornea, iris-ciliary body and bloodretina barrier; adipose tissue; and immune cells 10, [13] [14] [15] [16] [17] [18] [19] [20] (Table 1) . hOCT1 expression in tumours has also been broadly reported, 10, [21] [22] [23] although in some cases its expression levels may be downregulated when compared with surrounding normal tissue, as recently shown for liver cancer. 24 In summary, the anatomical distribution of hOCT1 in most epithelial barriers anticipates a major role for this membrane transporter in controlling drug pharmacokinetics and, eventually, pharmacodynamics. hOCT1 was originally included in the first set of human transporters relevant to drug development by the International Transporter Consortium. 25 Human OCT1 can transport not only monovalent organic cations, but also some divalent organic cations, some weak bases and some non-charged compounds. Substrates of human OCT1 include model cations, endogenous compounds and drugs among others. Some of the model compounds used to asses hOCT1 activity are tetraethylammonium, 1-methyl-4-phenylpyridinium and 4-[4-(dimthylamino)-styryl]-N-methylpyridinium. Endogenous compounds transported by human OCT1 include choline, acetylcholine, the neuromodulators histidyl-proline diketopiperazine (cyclo(His-Pro)) and salsolinol, the L-arginine metabolite agmatine, the polyamine putrescine and vitamine B1. 10, [26] [27] [28] Drugs transported by hOCT1 include metformin, used for the Figure 1 . Alignment of the organic cation transporter of different species. In orange the conserved amino-acid residues are highlighted.
Drug pharmacogenetics and SLC22A1 polymorphisms C Arimany-Nardi et al treatment of type-II diabetes and cancer; the antivirals lamivudine, acyclovir and ganciclovir; quinine, pentamidine and furamidine used as antiparasitic drugs; and the antineoplastic drugs oxaliplatin, picoplatin and cis-diammine(pyridine)chloroplatin(II) and bendamustine among others. 10, 22, [29] [30] [31] Moreover, hOCT1 also accepts toxins such as the carcinogens aflatoxin B1 and ethidiumbromide as substrates. 32 
SNPS
The SLC22A1 gene is highly polymorphic in humans. In 2002, Kerb et al. 33 described for the first time 25 polymorphic variants in Caucasians for this gene. Since then, over 1000 single-nucleotide polymorphisms (SNPs) have been identified, 22 of which have been related to the treatment outcome when drugs transported by this protein are being used. Out of these, 21 are located at the protein-coding region, causing all of them amino-acid substitutions, but one that results in an amino-acid deletion (M420del) ( Figure 2 ). The one left in this list is an intronic variant (rs622342). For a comprehensive overview of SLC22A1 gene heterogeneity, we refer to Tables 2-8 in this review. SLC22A1 genetic heterogeneity is ethnic-specific. Caucasian, African and American (Puerto Ricans, Colombian and Mexican) populations present higher variability than Asians and Pacific Islanders. Only one of the studied polymorphic variants (M408V) is present in all groups and is the only variant identified in Pacific Islanders. Three other variants (F160L, P341L and the intronic rs622342) are present in the rest of the groups with allelic frequencies higher than 1%, whereas R61C and M420del have been only identified in Caucasians, Africans and Americans.
Caucasian and American populations seem to share the specificity for SLC22A1 variants being G38D-, G401S-and G465R specific for these ethnic groups. The variants S14F, R342H, V461I, R488M and V519F are specific for Africans, all of them present at an allelic frequency higher than 1%. Two of the variants (P117L and P283L) are expressed exclusively in Asian population, although their allelic frequency is lower than 1%. The other studied variants (C88R, A99T, G174S, S189L and G220V) are expressed in less than 0.5% of the population. Interestingly, two of these polymorphic variants (C88R and G465R) have been observed only in combination with the variant M420del. The haplotype combining C88R and M420del is designed allele OCT1*6, whereas the haplotype with C88R and M420del is designed allele OCT1*5. Other alleles (OCT1*1-4) contain only one polymorphic variant and will be referred in this review by the SNP amino-acid change.
Many of SLC22A1 non-synonymous polymorphisms associated with altered function are located in conserved gene regions among orthologues, thereby suggesting a key role of these residues on functionality. In fact, some of these polymorphic variants are major contributors to variation in drug disposition, therapeutic and adverse drug responses and risk for human disease. Moreover, the potential pharmacokinetic consequences of hOCT1 polymorphic variants vary depending on the administrated drug, making it difficult to predict the effect of a polymorphism on the transport of a specific compound without directly testing that compound.
DRUGS AND PHARMACOGENOMICS
Drugs used in the treatment diabetes and polycystic ovary syndrome Metformin, a drug used for the treatment of type-II diabetes and cancer, was one of the first drugs described to be a hOCT1 substrate. It was also the first drug for which polymorphic variants of the transporter were studied for their effect on pharmacokinetics and pharmacodynamics. 34, 35 Nowadays, it can be considered as a sort of paradigm in drug transporter pharmacogenetics. In the seminal studies by the Giacomini laboratory, seven of the polymorphic hOCT1 variants (S14F, R61C, S189L, G220V, G401S, M420del and G465R) showed impaired metformin uptake. In particular, S14F, S189L, G401S and M420del were kinetically characterised yielding similar Km values to those described for the wild-type transporter, although V max was significantly reduced. A clinical study in healthy volunteers showed that plasma glucose levels after metformin treatment were significantly higher in volunteers carrying hOCT1 polymorphisms than in those carrying only reference hOCT1 alleles. Consistent with the difference in the plasma glucose levels after metformin treatment, insulin levels were significantly higher 2 h after glucose administration in individuals carrying loss-of-function variants compared with those carrying the wild type. 35 A further study showed an increase in the area under the concentration-time curve, higher maximal plasma concentration (C max ) and lower oral volume of distribution (V/F) in those individuals carrying reduced function alleles (R61C, G401S, M420del and G465R) compared with those carrying the wild-type transporter. 34 Tzvetkov et al. 12 observed in healthy volunteers that homozygous carriers of R61C, G401S, M420del and G465R presented increased renal clearance of metformin. This increase could not be detected in another study where the variants were expressed heterozygously. However, homozygous carriers for the minor allele in the intronic variant rs622342 showed significantly lower renal clearance of the drug. 36 In a clinical study with patients with type-II diabetes mellitus, only the variant rs622342 of all studied variant was associated with the glucose-lowering effect of metformin. In patients carrying this variant, the reduction of glycated haemoglobin (HbA1c) was lower than in those expressing the wild-type protein. 37 This variant was also assessed in diabetic Indian population and was found to be similarly associated with low response to metformin treatment. 38 The clinical impact of this variant is somehow controversial, because in the report by Christensen et al. this type of correlation was not found, in agreement with other studies focused on the impact of this variant on metformin action. 39, 40 Nevertheless, this association could be identified with the variant G401S, but only when short-term treatments were evaluated. 41 Patients expressing the variants R61C, G401S, M420del and G465R showed a metformin-induced HbA1c reduction similar to that achieved in patients bearing the wild-type transporter protein. 42, 43 Polymorphic variants in hOCT1 have not only been related to the metformin effect in type-II diabetic patients but also to secondary effects of the drug. The minor allele in the M408V variant and a 8-bp insertion (rs36056065) in the gene have been associated with the presence of common gastrointestinal side effects of metformin therapy, but not with the effectiveness of the treatment. In the same study, SNPs R61C, M420del and G465R showed no effect either on metformin action or in its secondary effects. 44 In women with Polycystic Ovary Syndrome, metformin effects were also related to OCT1 variants. The studied population was stratified based on the number of carried polymorphisms. They presented the polymorphic variants, R61C, G401S, G465R and M420del. Metformin significantly reduced total cholesterol or triglycerides in the reference group, but had no effect in subjects carrying variants, regardless of the number of polymorphisms. However, the effect of metformin on glucose-stimulated insulin secretion was influenced by the number of OCT1 polymorphisms. Thus, insulin area under the concentration-time curve was similarly decreased in the reference group or in individuals expressing one polymorphism, but did not significantly change in patients carrying two or more polymorphisms. 45 In Asian population, the role of OCT1 polymorphic variants in metformin handling has also been studied. The uptake of metformin was significantly reduced in cells expressing Q97K, P117L and R206C compared with the wild-type OCT1. 46 Kinetic studies indicated that P117L and R206C had a reduced V max , whereas Q97K showed an increased Km for the drug. Nevertheless, the allelic frequency for these variants was so low that no clinical studies could be performed. In a clinical study in healthy subjects, the variant P341L showed a trend towards higher area under the concentration-time curve and C max values compared with the reference OCT1, although the difference was not statistically significant. 47 Two other variants were found in Asian population to be either positively (M408V) or negatively (−43T4G in intron 1) correlated with metformin efficacy. In fact, the hepatic expression of OCT1 in individuals expressing the M408V variant tends to be lower than in those were the reference variant is expressed. 48 Drugs used in antiviral treatments Lamivudine, an antiretroviral drug, is also a hOCT1 substrate. 30 Importantly, hOCT1 is known to be expressed and regulated in most immune system cells. Its expression in CD4 + cells is particularly relevant as long as this is a major HIV1 target being this transporter protein a major determinant of drug accumulation within cells. 49 Polymorphic variants C88R and G465R showed complete loss of function when assayed for lamivudin uptake. Variants R61C, S189L and M420del presented a significantly decreased V max , although only S189L showed a significantly decreased affinity for the drug. In all polymorphic variants studied so far, transport efficacy was significantly altered (Arimany-Nardi et al., in preparation). Moreover, when two common Asian variants (P283L and P341L) were tested for lamivudine transportability, both were shown to be less active for lamivudine uptake. In fact, kinetic studies revealed a significantly reduced V max without changes in substrate affinity. 50 Drugs used in anticancer therapy Bendamustine is indeed an old drug but a very new one in the context of chronic lymphocytic leukaemia treatment. Bendamustine Drug pharmacogenetics and SLC22A1 polymorphisms C Arimany-Nardi et al G174S  ND  ND  ND  ND  ND  ND  ND  ND  ND  3 rs34104736 566C4T S189L G38D  0  0  ND  1  rs12208357 181C4T  R61C  0.01  ND  0  1  rs55918055 262T4C  C88R  ND  ND  0  1  295G4A  A99T  ND  ND  ND  1  rs200684404 350C4T  P117L  ND  ND  ND  2  rs683369  480C4G  F160L  0.005  ND  ND  3  520G4A  G174S  ND  ND  ND  3 rs34104736 566C4T S189L 0 0 0. 0  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  7  rs34130495 1201G4A  G401S  0  0  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  7 ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  7  rs72552763 1260 GAT4del  8  rs35956182 1320G4A  M440I  0  0  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  8  rs34295611 1381G4A  V461I  0  0  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  9  rs34059508 1393G4A  G465R  0  0  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  9  rs35270274 1463G4T  R488M  0  0  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  10  rs78899680 1555G4T  V519F  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  Intronic rs622342 A4C has recently been described to be a hOCT1 substrate, being bendamustine-induced cytotoxicity dependent on hOCT1 function. Two of the studied polymorphic variants (S189L and G465R) were not associated with hOCT1-mediated cytotoxicity, whereas R61C and M420del variants showed a decreased hOCT1-induced cytotoxicity when compared with the wild-type transporter. When these loss-of-function variants were evaluated in primary cells from chronic lymphocytic leukaemia patients, it was observed that a subset of chronic lymphocytic leukaemia cases showed a significant correlation between those cells expressing disfunctional variants of the transporter and bendamustine ex vivo cytotoxicity. 31 Sorafenib is a novel tyrosine kinase inhibitor that has been reported to be beneficial in the treatment of hepatocellular carcinoma and cholangiocarcinoma. A recent study identified hOCT1 as a sorafenib transporter, although previous studies ruled out the possibility of hOCT1 mediating sorafenib uptake. 51, 52 Two novel variants, hOCT1-R61S and hOCT1-C88A, which were identified either in hepatocellular carcinoma, cholangiocarcinoma or both but not in the adjacent healthy tissue, showed impaired sorafenib transportability that may affect the ability of this drug to reach active intracellular concentrations in tumours retaining hOCT1 expression. 51 Interestingly, Zebularine, an epigenetic drug that is being developed for the treatment of the myelodysplastic syndrome, has been shown to be extruded by the wild-type form of hOCT1. Accordingly, when the polymorphic variants C88R, M408V, M420del and G465R were tested for their efflux capacity, drug efflux was significantly lower than that observed in the wild-type form in all cases. 53 Although this would require further clinical assessment, it is tempting to speculate that, in case hOCT1 is behaving as an efflux instead of an influx drug transporter, loss-offunction variants would be associated with increased drug sensitivity.
Imatinib, is a tyrosine kinase inhibitor currently used in the treatment of chronic myeloid leukaemia (CML). Although some in vitro studies indicated that imatinib is a weak or even is not a hOCT1 substrate, 54, 55 some studies have reported that hOCT1 expression and its associated activity may be the most important determinants for imatinib treatment outcome in CML patients. [56] [57] [58] The role of the transporter polymorphic variants on the pharmacokinetics of this drug and its clinical response is also controversial. Kim et al. 59 determined that the polymorphic variant L160F was responsible for a higher rate of loss of response to imatinib in a cohort of 229 patients. However, a further study in a smaller cohort of 33 patients showed no correlation between this polymorphic variant and response to treatment. 60 All studies involving the R61C variant showed no correlation between its occurrence in patients and response to imatinib. [61] [62] [63] [64] Otherwise, patients carrying the G401S variant showed high probability of achieving major molecular response to the drug. 64 Takahashi et al. 65 determined that Japanese patients, carrying the polymorphic variant M408V, showed significantly major molecular response compared with those carrying the wild type. In addition, the haplotype implicating this polymorphic variant with the two intronic variants rs3798168 and rs80301372 was shown by others to be significantly associated with diminished imatinib clearance. 66 Another study in Caucasians could not demonstrate any significant correlation between this variant and overall inadequate response to imatinib. 63 Another polymorphic variant with high allelic frequency in Asians, P341L, has been repeatedly reported not to be associated with altered imatinib pharmacokinetics and drug response. [67] [68] [69] However, this was not the case in a study with mixed Caucasian, Asian and African patients, in which an association between this polymorphic variant and cytogenic response to imatinib was observed. 70 This apparent controversy involving hOCT1 polymorphic variants and imatinib, has also been found when addressing the pharmacogenetic impact of the Caucasian and American highallelic-frequent variant M420del. No correlation was observed with overall response to the treatment in two independent studies, 62, 63 whereas a recent clinical study in newly diagnosed CML patients showed that this polymorphic variant could modulate the outcome during imatinib treatment, showing significant correlation with a higher risk of treatment failure. 71 In addition, the SNPS combination, R61C, L160F, P341L and M420del were shown to be significantly associated with imatinib response. 70 Although imatinib does not seem to be translocated by hOCT1, 55 the presence of the transporter as well as some of its polymorphic variants have widely reported to affect outcome. Thus, it is tempting to speculate that hOCT1 expression is either linked to the expression of other transporters and/or metabolic proteins relevant to imatinib efficacy, or hOCT1 polymorphic variants show genetic linkage to other genes that can indeed contribute to imatinib therapeutic response.
Other drugs O-desmethyltramadol, the active form of tramadol, is internalised through hOCT1. Polymorphic variants R61C, G401S, M420del and transporters bearing those combinations of amino-acid substitutions more commonly found as polymorphisms in Caucasian population (M420del/C88R and M420del/G465R) alleles OCT1*5 and *6 showed impaired O-desmethyltramadol uptake compared with the wild-type transporter. Clinical studies demonstrated that those individuals carrying loss-of-function variants presented higher plasma concentrations of the drug associated with high concentrations in the central nervous system and increased stimulation of the μ-opioid receptor. 72 Morphine, is a high-affinity hOCT1 substrate. However, the polymorphic variant G401S as well as the haplotypes OCT1*5 and OCT1*6 were not able to transport morphine. R61C and M420del showed low morphine transport capacity (V max ) compared with the wild-type protein without significant changes in substrate affinity, despite a tendency to increased Km reported for the M420del variant. In a clinical study involving healthy volunteers, all these hOCT1 variants were considered to be non-functional. Individuals carrying a loss-of-function allele had significantly higher plasma concentrations of morphine than those found in the non-carriers. The maximal plasma concentration showed also a strong trend to increase along with the number of loss-offunction hOCT1 alleles. 73 In a parallel clinical study in children, mean individual morphine clearence in subjects homozygous for defective hOCT1 alleles was significantly lower than clearence found in carriers of the active OCT1 allele. 74 The antihypertensive drug debrisoquine has also been shown to be translocated by hOCT1. The analysis of the funcional impact of its polymorphic variants on drug uptake showed that the R61C, G401S and M420del variants presented a decreased V max compared with the wild type, whereas the Km value was not significantly affected. The haplotypes OCT1*5 and OCT1*6 resulted in a complete loss of function for debriosquine transport. 75 The antiemetic drug topisetron, is also a hOCT1 substrate. This drug is primarily metabolised by the hepatic enzyme CYP2D6. Thus, in order to be metabolised, it has to be internalised into hepatocytes by hOCT1. In this context, transporter polymorphic variants have been postulated to alter drug response. A recent study by Tzvetkov et al. showed an increase in drug plasma concentrations and response to treatment in patients carrying reduced functioning hOCT1 variants (R61C, G401S, M420del and the haplotypes OCT1*5 and OCT1*6) independently of CYP2D6 genetic variability. Although ondansetron inhibited the uptake of 1-methyl-4-phenylpyridinium mediated by hOCT1, direct uptake of the drug could not be measured. Nevertheless, similar to what was observed with topisetron, ondansetron plasma concentrations were higher in patient lacking any fully active hOCT1 allele Drug pharmacogenetics and SLC22A1 polymorphisms C Arimany-Nardi et al and decreased with the increasing number of fully active hOCT1 alleles. When drug effect was assessed by number of vomiting episodes in the first 24 h after chemotherapy, those patients carrying lacking-of-function alleles vomited less frequently than those with one or two functional alleles in agreement with the observed increased plasma concentration. The effect was significant in the subgroup of patients that received topisetron, but not in the subgroup treated with ondansetron although a similar trend could be observed. When the group of patients treated with ondansetron was enlarged, the significance for this drug could be also determined. 76 Finally, the minor C allele at rs622342, the intronic variant that was previously shown to be associated with metformin response, was also associated with higher prescribed doses of anti-Parkinsonian drugs and shorter survival after levodopa therapy. The exact drug or drugs that contributed to the difference in prescribed daily dose of anti-Parkinsonian drugs could not exactly be identified. The only drug for which the prescribed daily doses were significantly associated with rs622342 was amantadine. However, it could not be excluded that the polymorphic variant was associated with lower response to levodopa, and that this had to be compensated by prescribing higher doses of amantadine. 77 The psychotropic drugs amisulpride and sulpride have recently been reported to be hOCT1 substrates also. In vitro studies showed that the hOCT1 polymorphic variants R61C, G401S and M420del, as well as the haplotypes OCT1*5 and OCT1*6 resulted in decreased drug uptake. 78 Vitamine B1 has recently been identified as a hOCT1 substrate. In vitro studies showed that hOCT1 polymorphic variants R61C, S189L, G220V, G401S, M420del and G465R affected vitamine B1 uptake. 28 
DRUG-DRUG INTERACTIONS
Polymorphic hOCT1 proteins have shown to be more susceptible to inhibition by drugs compared with a hOCT1 reference. For metformin, variants R61C and M420del, were more sensitive to drug inhibition, with half maximal inhibitory concentration up to 23 times lower than those of OCT1 reference. The concomitant administered drugs, verapamil and amitriptyline, revealed potential drug-drug interactions at clinical plasma concentrations of metformin for M420del. 79 A study with lamivudine and co-administered antivirals showed that, at C max concentrations, abacavir, zidovudine, efavirenz and raltegravir could significantly inhibit lamivudine uptake mediated by M420del. Abacavir was also able to inhibit the uptake mediated by R61C, whereas it increased significantly the uptake of lamivudine when raltegravir was co-administered. Efavirenz, otherwise, did not affect lamivudine uptake mediated by this polymorphic variant when compared with the OCT1-reference transporter. Moreover, the 
R61C
↓ Uptake
G401S
↓ Uptake M420del ↓ Uptake OCT1*5 ↓ Uptake OCT1*6 ↓ Uptake Vitamin B1 28 R61C ↓ Uptake S189L
↓ Uptake G220V
↓ Uptake G401S
↓ Uptake M420del
↓ Uptake G465R
The colour code reflects the population in which the polymorphic variant is more present; african (purple); caucasian and american (green); asian (yellow); rare variant (pink). All cited variants in the table present a reduced tranport activity. a only in short-term treatments. S189L hOCT1 variant was significantly more prone to be inhibited by efavirenz than the hOCT1 reference (Arimany-Nardi et al., in preparation). In summary, as comprehensively reviewed above, current knowledge on hOCT1-related drug pharmacogenetics anticipates polymorphisms can significantly modify drug pharmacokinetics and pharmacodynamics, particularly in those patients under combined therapies involving hOCT1 substrates. However, clinical knowledge in this regard is very limited and requires further experimental assessment.
FUTURE PERSPECTIVES
In summary, there is consistent clinical data supporting the view that hOCT1 polymorphic variants have a significant role in the pharmacokinetics and pharmacodynamics of those drugs that are translocated across the plasma membrane by this transporter protein (see Table 9 as a summary). At this moment, SLC22A1 genetic heterogeneity and its impact on drug action can be considered as a paradigm in drug transporter pharmacogenetics. Moreover, genetic heterogeneity may be thus important not only in monotherapy but also in patients under combined therapies. This may become a clinically relevant issue, because hOCT1 polymorphic variants appear to differently affect substratetransporter interaction, thereby making it difficult to generalise the role a particular polymorphic variant might have in drug bioavailability and action.
hOCT1 modelling might prove useful for anticipating altered substrate binding, but transporter translocation cycles are complex and structural information is still scarce. Moreover, some variants are located in residues that do not appear to directly contribute to translocation itself, but rather to oligomerization, thereby making still necessary the use of engineered cell lines stably expressing these hOCT1 variants for experimental assessment of drug-transporter interaction and further optimisation of drug treatment.
Moreover, the possibility of hOCT1 genetic heterogeneity contributing to disease progression cannot be ruled out and deserves further analysis. In fact, selected SLC22A1 gene variants have been correlated with the progression of primary biliary cirrhosis in Japanese patients. 80 This means that hOCT1 is likely to have a role in pathogenesis beyond its primordial function as a drug transporter. Furthermore, the abundance of hOCT1 protein may be also dependent on genetic heterogeneity affecting SLC22A1 gene transcriptional performance. hOCT1 expression in the liver appears to be strongly determined by hepatocyte nuclear factors-1α and -4α. 81, 82 The recent finding that genetic variants in transcription factors, including hepatocyte nuclear factor-4α, can determine metformin action 83 similarly anticipates that hOCT1 transporter expression and function may be the result of a genetic heterogeneous network globally determining transporter performance and thus, drug action.
